Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q08043

UPID:
ACTN3_HUMAN

ALTERNATIVE NAMES:
Alpha-actinin skeletal muscle isoform 3; F-actin cross-linking protein

ALTERNATIVE UPACC:
Q08043; A6NP77; Q4KKV2

BACKGROUND:
The protein Alpha-actinin-3, alternatively named F-actin cross-linking protein, is integral to the structural organization of skeletal muscle. It facilitates the cross-linking of F-actin, thereby anchoring actin to a multitude of intracellular components. This action is vital for maintaining the mechanical stability and functionality of muscle fibers.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Alpha-actinin-3 unveils potential pathways for therapeutic advancements. Given its significant role in muscle structure and function, targeting this protein could lead to innovative treatments for enhancing muscle performance and addressing muscular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.